, but it remains unknown whether they are linked to dysmaturational processes crossing diagnostic boundaries, aggravating across disease stages, and driving the neurodiagnostic signature of the illness. Therefore, we investigated whether patients with SZ (N = 141), major depression (MD; N = 104), borderline personality disorder (BPD; N = 57), and individuals in at-risk mental states for psychosis (ARMS; N = 89) deviated from the trajectory of normal brain maturation. This deviation was measured as difference between chronological and the neuroanatomical age (brain age gap estimation [BrainAGE]). Neuroanatomical age was determined by a machine learning system trained to individually estimate age from the structural magnetic resonance imagings of 800 healthy controls. Group-level analyses showed that BrainAGE was highest in SZ (+5.5 y) group, followed by MD (+4.0), BPD (+3.1), and the ARMS (+1.7) groups. Earlier disease onset in MD and BPD groups correlated with more pronounced BrainAGE, reaching effect sizes of the SZ group. Second, BrainAGE increased across at-risk, recent onset, and recurrent states of SZ. Finally, BrainAGE predicted both patient status as well as negative and disorganized symptoms. These findings suggest that an individually quantifiable "accelerated aging" effect may particularly impact on the neuroanatomical signature of SZ but may extend also to other mental disorders.
Introduction
From adolescence to adulthood, the brain's neural architecture is profoundly remodeled, involving synaptic elimination, dendritic pruning, and myelination. 1 At the macroscopic level, significant gray matter (GM) reductions within the prefronto-temporo-limbic cortices may reflect this maturational process, which shapes the substrate of complex and integrated behavior in adult life. Importantly, these age-related changes seem to be so well conserved across individuals that they constitute a tightly controlled intermediate phenotype of normal brain maturation, 2 which enables the single-subject quantification of abnormal age-related neurodevelopment by using magnetic resonance imaging (MRI)-based multivariate pattern analysis (MVPA).
Accelerated Brain Aging in Schizophrenia and Beyond
This hypothesis requires thorough evaluation by contrasting disease-specific findings with changes in the normally maturing brain. 12 Furthermore, because considerable neuroanatomical overlaps have been found between nonaffective and affective psychoses, 13 it remains unclear if maturational processes may only be altered in SZ or across nosological boundaries. Finally, previous MRI studies revealed high diagnostic classification rates (70%-90%) of patients with schizophrenic or affective psychoses vs healthy controls (HCs).
14 It is unknown whether the diagnostic signatures underlying these results emerge from an altered neurodevelopment in SZ and beyond. This question is of crucial relevance for future imaging-based diagnostic tools in psychiatry because disease-specific deviations from the normal maturational trajectories may evolve dynamically, thus determining the diagnostic performance of MRI-based biomarkers across the life span. 15 To investigate these questions, we first constructed a multivariate model of neuroanatomical brain maturation enabling the single-subject estimation of age in a large MRI database of HCs. Then, this age predictor was applied to a transnosological database of different diagnostic groups that include patients with SZ, major depression (MD), borderline personality disorder (BPD), and individuals in at-risk mental states (ARMS) for psychosis in order to quantify their deviations from the normal maturational trajectory using brain age gap estimation (BrainAGE). 4 Furthermore, BrainAGE was used to compare disease stages of SZ, consisting of early and late ARMS (ARMS-E and ARMS-L, respectively), recent-onset (RO), and recurrently ill (RE) SZ patients. Moreover, we assessed whether BrainAGE determined a separately trained MVPA classifier's ability to individually separate SZ, MD, and BPD patients from HCs. Finally, we examined the impact of sociodemographic and clinical variables on BrainAGE variation in SZ patients and HCs. We expected to find (1) BrainAGE increments predominantly in SZ group compared with MD and BPD groups, in line with the "accelerated aging" hypothesis of SZ, 10, 11 and (2) an increasing BrainAGE gradient from ARMS through RE-SZ individuals. We hypothesized that BrainAGE predicts the single-subject separability of SZ, MD, and BPD patients vs HCs due to a considerable overlap of age-and disease-related brain variation.
Methods

Study Participants
A structural MRI database of 800 HCs, aged 18-65 and recruited across 5 centers, was created in order to train the multivariate age predictor (definitions are given in 21 in SZ and BPD groups, the Scale for the Assessment of Negative Symptoms 22 in SZ group, and the Hamilton Depression Rating Scale 23 in MD and BPD groups. A consensus diagnosis was achieved by two experienced psychiatrists at study inclusion and after 1 year using the DSM-IV. Doses of antipsychotic medications at MRI were converted to chlorpromazine equivalents. 24 Additionally, a sample of 89 ARMS individuals was generated by pooling the Munich (N = 52) and Früherkennung von Psychosen (FePsy) 25 (N = 37) databases. In both databases, an ARMS-L for psychosis was defined by established operationalized ultrahigh-risk criteria (table 1) . The Munich sample also included individuals with ARMS-E (table 1). Seventytwo ARMS individuals were regularly followed over 4-7 years to detect a disease transition, as defined by psychotic symptoms occurring daily and persisting for more than 1 week. 19 Transition to SZ (N = 29) or schizoaffective psychosis (N = 4) occurred in 33 individuals. Diagnoses were confirmed by DSM-IV criteria 1 year after transition. Only 4 ARMS subjects received atypical antipsychotics (3 olanzapine and 1 risperidone) for less than 3 weeks prior to MRI scanning. Symptom severity was measured using the PANSS in the Munich sample and Brief Psychiatric Rating Scale in the FePsy sample.
SZ patients with an illness duration of <1 year, no previous inpatient treatment, and <12 months (lifetime) of antipsychotic treatment were assigned to the RO-SZ subgroup or to the RE-SZ sample if not fulfilling these criteria. Illness duration was the time interval between MRI scanning and disease onset defined retrospectively by the onset of symptoms paralleled by a general decline in social and role functioning. 26 All participants gave their written informed consent prior to study inclusion. The study design was approved by the local ethics committee and was prepared in accordance with the ethical standards of the Declaration of Helsinki.
MRI Data Acquisition and Preprocessing
All MR images were processed using the VBM8 toolbox 27 and SPM8 software, which generated GM maps in the original MRI space of each participant (table 2;  online supplementary methods 1) . 28 Then, a dual registration strategy captured both large-scale and focal neuroanatomical variation in the study population: first, the GM maps were affinely registered to the single-subject Montreal Neurological Institute template, thus removing global brain volume differences across subjects N. Koutsouleris et al while retaining large-scale, interindividual morphometric variation. Second, these maps were high dimensionally registered to the template using the DRAMMS algorithm, 29 which encoded focal, nonlinear tissue deformations in each individual brain relative to the template. The resulting deformations and warped tissue maps were used to compute GM maps allowing for a Regional Analysis of brain Volumes in Normalized Space (GM-RAVENS). 30 
Support Vector Regression for MRI-Based Age Prediction
Across diverse biomedical fields, support vector machines (SVM) demonstrated their ability to learn multivariate prediction rules that generalize well across study populations, thus enabling individualized diagnostic classification and function approximation (online supplementary methods 2). 31 We used linear ν-support vector regression (ν-SVR) 32 to predict age from each subject's MRI by constructing predictive models from one set of subjects (the training sample) and applying them to a different set of subjects (the test sample), using cross-validation (CV). 33, 34 This produced a completely unbiased estimate of the method's age prediction performance in new individuals, rather than merely fitting the current study population. More specifically, our prediction pipeline was wrapped into a repeated nested CV framework consisting of 10 repetitions × 10 ms folds at the outer and inner CV cycles, as detailed previously. 33, 34 Each training sample at the inner CV loop was processed as follows: first, the multivariate RGS (Regression, Gradient guided Feature selection) algorithm 35, 36 ranked voxels in the GM-RAVENS and affine maps according to their age prediction relevance. Each GM input space was scaled using the respective weight vectors and projected to 400 predictive using principal component analysis (PCA). 18 Finally, the ν-SVR generated a linear kernel projection from the training cases' eigenvariate loadings and determined an optimal age-fitting function in kernel space. Fitting was controlled by the ν-SVR's parameters, which were optimized in the inner CV cycle.
Each test person's age was estimated by applying the trained prediction system (RGS, PCA, and ν-SVR models) to the respective test data. Age estimations were averaged across those models, for which the test person had not been involved in the training process. This out-of-training prediction performance was quantified using the mean absolute error (MAE) and explained variance (R 2 ). Individual errors were measured using BrainAGE. 4 Finally, the trained predictor was applied to the 302 patients (SZ, MD, and BPD) and the 89 ARMS individuals to obtain BrainAGE scores. Additionally, we evaluated whether an age prediction system trained only in the Munich HC database would considerably change the results of our analyses (online supplementary analysis 3).
BrainAGE analyses
Sociodemographic, clinical, and BrainAGE group-level differences were assessed across HC 1 , SZ, MD, BPD, and ARMS samples (analysis 1) and HC 2 , ARMS-E, ARMS-L, RO-SZ, and RE-SZ groups (analysis 2) (table 3; figure 1 ). Continuous variables were evaluated using ANOVAs, and categorical variables were evaluated using χ 2 tests. Significance was defined at P <.05. For the patient groups in analysis 1, we further assessed main BrainAGE effects of diagnosis, age of disease onset, and illness duration as well as the predictor × group interactions using ANCOVA. In analysis 2, we additionally evaluated main BrainAGE and interaction effects of disease stage (RO-SZ vs RE-SZ), age of onset, and symptom severity (PANSS total). Furthermore, effects of sociodemographic and clinical variables on BrainAGE were explored in the ARMS, patient (table 4), and HC groups (online supplementary analysis 1). Finally, we assessed whether a multivariate set of 62 clinical variables allowed for the single-subject prediction of BrainAGE in 125 SZ patients using ν-SVR regression (online supplementary analysis 2).
Single-Subject Patient Separability and Individual BrainAGE Scores
To evaluate the influence of BrainAGE on MRI-based patient classification, we trained a ν-SVM classifier (ν-SVC) to distinguish between 302 patients (SZ, MD, and BPD) and 302 age-and sex-matched HCs from the Munich database. As previously described, we entered both GM-RAVENS and affine GM maps into a 3-step machine learning pipeline, consisting of multivariate voxel weighting, PCA, and ν-SVC. Again, all computations were wrapped into repeated, nested CV, as described above. 20, 33, 34 The SVM's ν hyperparameter was a priori set to 0.5.
The trained classifier was applied to the test cases resulting in group predictions and decision values measuring the distance between the respective subject and the SVM's decision boundary. The out-of-training classifier performance was quantified as accuracy and area under the curve (AUC) (figure 2). Correlations between patient separability (decision values) and BrainAGE as well as overlaps between patient-and age-predictive patterns were shown in figure 2.
Results
Sociodemographic and Clinical Parameters
The HC 1 , patient (SZ, MD, and BPD), and ARMS groups differed regarding age, sex, education, and nicotine consumption (table 3) . Illness onsets and durations varied significantly between patient groups: BPD group started earliest and showed longer duration compared with SZ (P < .001) and MD (P = .006) groups. The MD group was characterized by the latest onset: mean (SD): 36.5 (12.0) years, whereas SZ commenced at mean (SD): 24.2 (6.2) years. As expected, antipsychotic medication at MRI was more prevalent in SZ (90%) vs MD, BPD, and ARMS groups, whereas antidepressants were more prevalent in MD (73.1%) vs the other groups (table 3) . Mood stabilizer prescription was low, with BPD group showing the highest prescription rate (21.6%; table 3). HC 2 , ARMS-E, ARMS-L, RO-SZ, and RE-SZ groups differed regarding age, schooling years, body mass index, and nicotine consumption (table 3). PANSS total score was significantly higher in RE-SZ vs ARMS-E and ARMS-L (P < .001) groups, with the PANSS negative subscore in RE-SZ exceeding all other samples (table 3) . RE-SZ patients were more frequently treated with antipsychotics in general, atypical antipsychotics, and antidepressants compared with RO-SZ patients.
Individualized Age Prediction in HCs
The ν-SVR predictor estimated age with a MAE of 4.6 years (R 2 = .83; T = 62.7; P < .001) in single out-oftraining HCs (figure 3). Age-predictive brain regions are shown in figure 4 . , and ARMS (+1.7 [7.2] ) groups. Between-group differences were found in SZ vs BPD (P < .007) group, SZ vs ARMS (P < .001) group, and MD vs ARMS (P < .005) group.
BrainAGE Across Diagnoses
Furthermore, we detected an independent main BrainAGE effect of age of disease onset (F = 11.2; P < .001) across diagnoses but detected no effects of diagnosis, illness duration, or diagnosis × clinical predictor interactions. Post hoc regression analyses showed that MD (r = −.34, T = −3.23; P < .002) and BPD groups (r = −.42, T = −2.58; P < .014), but not the SZ group (r = −.07, T = −0.79; P < .432), were driving age of onset effects based on negative BrainAGE correlations. We further explored these effects by median-splitting samples and defining "early vs late onset" as factor in an additional ANCOVA. Again, main effects of this factor survived after controlling for diagnosis and illness dura- 
BrainAGE Across Stages of SZ
BrainAGE also varied across HC 2 , ARMS-E, ARMS-L, RO-SZ, and RE-SZ (F = 15.7; P < .001) groups, with increases in RE-SZ (+6.4 [5.6] y; P < .001), RO-SZ (+4.2 [6.4]; P < .001), and ARMS-L individuals (+2.7 [6.9]; P < .005) vs HCs (figure 1). Significant post hoc differences were found in the groups (1) RE-SZ vs RO-SZ (P < .034); ARMS-L (P < .001); and ARMS-E (P < .001), (2) RO-SZ vs ARMS-E (P < .001), and (3) ARMS-L vs ARMS-E (P < .005). A linear BrainAGE increase was detected from ARMS-E to RE-SZ (R 2 = .33; T = 5.3; P < .001), with the ARMS-E group showing negative BrainAGE effects. No main or interaction BrainAGE effects of disease stage (RO-SZ vs RE-SZ) and age of onset were found after controlling for PANSS total. However, the main BrainAGE effect of PANSS total survived after controlling for disease stage and age of onset (F = 4.4; P = .038).
BrainAGE Associations With Sociodemographic and Clinical Parameters
We did not observe any significant BrainAGE associations of psychotropic medications, nicotine, and alcohol in the patient (SZ, MD, and BPD) and ARMS groups (table 4) and no associations of sociodemographic parameters, nicotine/alcohol consumption, and different somatic conditions on BrainAGE in HCs (table 4; online supplementary analysis 1). A set of primarily negative and disorganized symptoms predicted BrainAGE in SZ subjects with R 2 = .26 (T = 6.5; P < .001; online supplementary analysis 2).
Associations Between BrainAGE and the SVM Classification of Patient Status
A cross-validated classification accuracy of 73.7% (AUC = 0.78) was observed in the SVM classification of 302 patients (SZ, MD, and BPD) vs 302 HCs (figure 2). Using BrainAGE as classifier in the same population, an accuracy of 65.7% (AUC = 0.71) was found at a cutoff value of +1.4 years. Classification accuracy for SZ patients vs HCs was higher both for the SVM (AUC = 0.81) and BrainAGE classifiers (AUC = 0.75). Average SVM decision and BrainAGE scores were highly correlated (R 2 = .53; T = 26.1; P < .001; figure 2 ). This correlation was due to a considerable overlap of age-predictive SVR patterns and brain regions involved in the SVM classification (figure 2).
Discussion
Studies recently employed MVPA methods to estimate age from structural MRI in large HC populations and reported very accurate prediction results across all ages and centers, with a minimum MAE of 1.1 years in children and adolescents. [2] [3] [4] Thus, age-related neuroanatomical variation seems to constitute a well-regulated intermediate phenotype of normal brain development enabling individualized age inference. To our knowledge, our study is the first to demonstrate that this phenotype is commonly aberrant across major psychiatric diseases and the prodromal state of psychosis, suggesting "accelerated aging" effects already in early schizophrenic psychosis, (1) the SVM decision values of 302 patients (PAT) vs 302 healthy controls (HCs) (blue line) and (2) the respective brain age gap estimation (BrainAGE) scores (red line). Upper right: regression analysis of BrainAGE scores vs SVM decision values in the same population. Lower panel: qualitative characterization of the neuroanatomical overlap (yellow) between the SVM weight vectors of the age prediction system (red) and the patient classifier (green). In the gray matter (GM)-Regional Analysis of brain Volumes in Normalized Space condition (left), this overlap involved perisylvian, orbitofrontal, medial prefrontal, medial parietal cortices, and subcortical structures. In the affine GM condition, the extended overlap of age-and patient-predictive regions covered perisylvian, temporal, occipital, parietal, lateral and medial prefrontal, orbitofrontal and medial parietal, thalamic, and cerebellar regions.
as well as in established MD and BPD. Moreover, these transnosological effects were more pronounced in earlyvs late-onset MD and BPD, thus rendering these subgroups indistinguishable from schizophrenic patients. This aligns with the clinical observation of an earlier occurrence of both illnesses being associated with a more debilitating disease course, such as a higher incidence of suicidal attempts, prolonged duration of disease episodes as well as higher levels of psychiatric comorbidity. [37] [38] [39] Furthermore, our finding of increased BrainAGE in early-onset MD and BPD supports the hypothesis that the disruption of normal brain maturation during specific and critical time windows in adolescence and early adulthood constitutes a neurobiological predisposition for the development of psychopathological abnormalities across the affective and psychotic disease spectrums. 1, 7 Prospective MRI studies of normally developing individuals demonstrated a spatially and temporally asynchronous pattern of neuroanatomical brain maturation shifting from sensorimotor brain regions to higher order association cortices. 12, 40 This process has been interpreted as a sequence of excitatory synaptic overelaboration followed by a reduction of excitatory and increase of inhibitory synaptic density. 1 This synaptic maturation is paralleled by ongoing white matter myelination, thus leading to a profound remodeling of neural networks, which optimizes neural connectivity through the exact temporal coding of neural activity. 41 In this regard, recent neuroimaging studies of adolescent and adult schizophrenic patients suggested that the spatial pattern and intensity of neuroanatomical alterations in SZ may critically interact with the trajectory of maturational processes occurring in the normally developing brain: childhood-onset patients showed more pronounced neuroanatomical abnormalities in the sensorimotor and premotor cortices, whereas adult-onset patients were characterized by structural alterations in prefronto-temporo-limbic and subcortical brain regions. 7, 42 Our study of adult patients extends these findings because our analyses revealed that (1) age-and disease-predictive GM variation overlapped within a prefronto-temporo-limbic pattern identified by recent meta-analyses of SZ studies (figure 2), 13, 43 (2) an individual's deviation from the maturational reference trajectory considerably determined its likelihood of being classified as patient, particularly in SZ, 44 and (3) this signature of neuroanatomical dysmaturation was present across all diagnostic groups, correlating more with age of onset and symptom severity than with diagnosis. The latter finding agrees with previous studies revealing neuroanatomical patterns shared by affective and nonaffective psychoses, 13 as well as earlier disease onsets being paralleled by more pronounced brain abnormalities. 7 In this regard, our results may point to an age-dependent, transnosological domain of mental illness that may serve as a baseline for exploring more specific neuroanatomical biomarkers of different psychiatric phenotypes.
We did not observe significant associations between BrainAGE and illness duration in any of the patient groups, suggesting that BrainAGE does not capture progressive structural brain changes previously reported in severe mental disorders. 9 The finding of a linear BrainAGE increase from ARMS to RE-SZ individuals (figure 1) rather suggests that BrainAGE represents a neuroanatomical vulnerability marker, whose expression parallels the accumulating risk for adverse disease outcomes: risk for disease onset (ARMS-E: 7% transitions, ARMS-L: 57% transitions over 4 y) and risk for relapsing disease in RE-SZ vs RO-SZ patients. It is of note that the ARMS-E group showed a "decelerated brain aging" effect, which might be interpreted as a compensatory neural mechanism or maturational delay, as suggested by Douaud et al. 42 However, due to the cross-sectional design of our study, these observations do not negate progressive structural brain alterations in the course of SZ and other psychiatric disorders. Progressive neuroanatomical abnormalities occurring after disease onset have been repeatedly reported by longitudinal studies 9 and have been linked to illness duration and antipsychotic treatment. 45 A likely interpretation of the nonsignificant associations between BrainAGE and these clinical variables (table 4; online supplementary analysis 2) may be that our multivariate age predictor spanned a analysis, which showed that 25% of BrainAGE variance in 125 SZ patients was primarily explained by negative and disorganization symptoms. This aligns with previous studies linking these symptoms to neuroanatomical abnormalities, 46, 47 cognitive deficits, and poor social functioning, 48 together forming a "syndrome of accelerated aging" in SZ. 11 Second, BrainAGE increases were already detectable in antipsychotic-naive ARMS-L individuals (+2.7 y). Because the illness duration in the RO-SZ patients was only 3.6 months and BrainAGE already measured was +4.2 years, an obvious interpretation may be that BrainAGE increases rapidly aggravate from attenuated psychosis to the established illness, in line with the hypothesis of a "late neurodevelopmental disturbance." 1, 5 Finally, in none of the patient groups we did detect correlations between BrainAGE and alcohol, nicotine, or psychotropic medications, including antipsychotics, antidepressants, and mood stabilizers (table  4) . Furthermore, we did not find significant effects of alcohol, smoking, educational, marital and occupational status as well as of major somatic conditions on BrainAGE in HCs (online supplementary analysis 1). These negative findings may further support a selective sensitivity of BrainAGE for abnormal neurodevelopment in severe mental illness. In summary, our results suggest that the BrainAGE framework provides a transnosological biomarker that (1) results from a disruption of normal brain maturation shared by different psychiatric phenotypes, (2) determines the case-by-case diagnostic performance of MRI-based disease classifiers, and (3) quantifies the risk for unfavorable clinical outcomes. Future investigations should thoroughly reevaluate the trait vs state nature of BrainAGE abnormalities and their specificity for neurodevelopmentally mediated mental illnesses by linking BrainAGE dynamics to the clinical, neurocognitive, and genetic dimensions of psychiatric disorders. 49, 50 
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